Christopher Rex
Gründer bei Afraxis, Inc.
Profil
Christopher Rex is the founder of Afraxis, Inc. which was founded in 2010, where he holds the title of Chief Scientific Officer.
He was also a Program Director at T123 LLC from 2018 to 2021.
Dr. Rex received his doctorate from the University of California, Irvine in 2008 and his undergraduate degree from the University of California, Santa Barbara in 2002.
Aktive Positionen von Christopher Rex
| Unternehmen | Position | Beginn |
|---|---|---|
Afraxis, Inc.
 Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Gründer | 01.01.2010 |
Ehemalige bekannte Positionen von Christopher Rex
| Unternehmen | Position | Ende |
|---|---|---|
T123 LLC
 T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California. | Direktor/Vorstandsmitglied | 01.04.2021 |
Ausbildung von Christopher Rex
| University of California, Irvine | Doctorate Degree |
| University of California, Santa Barbara | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Health Technology |
T123 LLC
T123 LLC Investment ManagersFinance I2020 Accelerator (I2020 Accelerator) is a venture capital firm founded in 2018. The firm is headquartered in San Diego, California. | Finance |
